2024 年全球生技投资成长机会

Growth Opportunities in Global Biotech Investment, 2024

出版日期: 2024年04月09日 | 出版商:

Frost & Sullivan | 英文 55 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

领先生物製药公司的颠覆性技术和投资组合重组确保了生物技术投资的成长潜力

在这份分析中，Frost & Sullivan 提供了有关生物技术併购和创业投资(VC) 投资的重要见解，确定了生物技术领域的驱动因素、挑战、预测和主要趋势。该分析还确定了行业参与者可以利用的成长机会。

为了了解 2024 年以后的趋势前景，本分析评估了 2019 年至 2023 年的策略和金融投资、併购）、创投和私募股权(PE)。 Frost & Sullivan 收集了整个生态系统的总数。然而，仅分析不涉及小分子资产的生物技术/生物製药交易。本分析的范围是以2023年为基准年的全球，并包含截至2028年的预测。

该评估不包括债务或未决事项。由于资料基于二手信息，因此处理的数量和金额可能会有所不同。同样，生物技术的定义也各不相同。一些资讯来源在公告日期记录併购交易，资讯来源记录交易进度的里程碑，还有资讯来源记录交易结束后的总金额。

生长促进因子
成长抑制因素
生物产业现况-生技药品管线
生物产业现况-生技药品产业前景
生技併购投资展望 - 2024 年
生技创投展望 – 2024
2024 年三大预测
大型药厂重塑投资组合的三大投资策略
新兴生物技术公司的趋势 - 影响摘要
新模式持续推动精准医疗的发展
投资者优先考虑心臟代谢、肿瘤学、中枢神经系统和免疫学

成长动力：生技併购

Bioventure併购趋势
主要生物製药公司併购活动
生物技术併购分析：按治疗领域
生物技术併购分析：依方式分类
2024年生物製药主要併购目标

成长动力：Bioventure VC投资

生技企业的融资趋势
顶级风资金筹措项目
Bioventure投资项目分析：依资金筹措阶段
Bioventure投资项目分析：依治疗领域
Bioventure投资项目分析：依模式
生物创投专案分析：依临床开发阶段

活跃公司

谷歌创投（美国）
ARCH 创投公司（美国）
RA资本（美国）
SamsaraBio资本（美国）
奥博医疗（美国）
亚历山大（美国）

成长机会宇宙

成长机会一：收购一家专注于罕见疾病的生物製药公司
成长机会二：投资以精准医疗平台技术为基础的生技公司
成长机会3：投资临床阶段的中国生物製药公司

最佳实践评估

最佳实践评估

弗罗斯特雷达

Frost Radar

下一步

成长机会的好处和影响
下一步
下一步
图表列表
免责声明

简介目录

Product Code: PFGA-52

Big Biopharma Companies Disruptive Technologies and Portfolio Realignment Will Ensure the Growth Potential of Biotech Investments

In this analysis, Frost & Sullivan provides critical insights into the biotech M&A and venture capital (VC) investment, highlighting the drivers, challenges, predictions, and major trends in the biotech segment. This analysis also identifies actionable growth opportunities for industry participants to leverage.

To understand the trend outlook for 2024 and beyond, this analysis assesses strategic and financial investments, mergers and acquisitions (M&A), VC investments, and private equity (PE) from 2019 to 2023. Frost & Sullivan has gathered the total numbers for the entire ecosystem. However, the analytics only include the biotech/biopharma deals not involving small-molecule assets. The scope of this analysis is global, with 2023 as its base year, and includes forecasts up to 2028.

This assessment does not include debt deals and open deals. The deal volumes and values can vary because the data comes from secondary sources. Similarly, definitions for biotech vary. While certain sources record an M&A deal on the announcement date, some record the milestones as the transaction goes through, and others record the total value after completing the transaction.

Transformation in Global Biotech Investment

Why is it Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top 3 Strategic Imperatives on Global Biotech Investments

Ecosystem

Market Scope and Segmentation
Definitions

Growth Generator

Growth Drivers
Growth Restraints
The State of the Biotech Industry-Biologics Pipeline
State of the Biotech Industry-Biologics Industry Outlook
Biotech M&A Investment Outlook-2024
Biotech VC Investment Outlook-2024
Top 3 Predictions-2024
Top 3 Big Pharma Investment Strategies for Portfolio Remodeling
Emerging Biotech Companies Top Trends-Impact Summary
New Modalities Driving Precision Medicine Will Remain Attractive
Investors Prioritizing Cardiometabolism, Oncology, CNS, and Immunology

Growth Generator: Biotech M&A

Biotech M&A Trends
Big Biopharma M&A Activity
Biotech M&A Analysis by Therapeutic Segment
Biotech M&A Analysis by Modality
Key Biopharma M&A Targets2024

Growth Generator: Biotech VC Investment

Biotech VC Financing Trend
Top VC Financing Deals
Biotech VC Deal Analysis by Funding Stage
Biotech VC Deal Analysis by Therapeutic Segment
Biotech VC Deal Analysis by Modality
Biotech VC Deal Analysis by Stage of Clinical Development

Companies to Action

Google Ventures (United States)
ARCH Ventures (United States)
RA Capital (United States)
SamsaraBio Capital (United States)
OrbiMed (United States)
Alexandria (United States)

Growth Opportunity Universe

Growth Opportunity 1: Acquiring Rare Disease-focused Biopharma Companies
Growth Opportunity 2: Investing in Precision Medicine Platform Technology-based Biotech Companies
Growth Opportunity 3: Investing in Clinical-stage Chinese Biopharma Companies